Atea Pharmaceuticals Announces Business Update at 7th Annual Evercore Conference
Atea Pharmaceuticals, Inc. is excited to share that their Chief Executive Officer and Founder, Jean-Pierre Sommadossi, PhD, will be participating in a fireside chat at the 7th Annual Evercore HealthCONx Conference on December 4, 2024, at 9:35 a.m. ET. During this time, the Atea management team will provide a business update as well.
A live webcast of the presentation will be available on the Atea Pharmaceuticals website. If you miss the live event, don’t worry – an archived webcast will be accessible on their website for at least 90 days after the conference.
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing oral antiviral therapies that tackle the unmet medical needs of patients suffering from serious viral infections. With their in-depth knowledge of antiviral drug development and nucleos(t)ide chemistry, biology, biochemistry, and virology, Atea has developed a proprietary nucleos(t)ide prodrug platform to create innovative product candidates to combat single-stranded ribonucleic acid viruses, which are often the cause of severe viral diseases.
Currently, Atea’s primary focus is on developing a combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. They plan to expand their pipeline of antiviral product candidates by incorporating other classes of antivirals that can be used alongside their nucleos(t)ide product candidates.
For more information about Atea Pharmaceuticals and their groundbreaking work, please visit their website at www.ateapharma.com.
